RG
NBIX icon

Redmile Group’s Neurocrine Biosciences NBIX Stock Holding History

Redmile Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,740
Closed -$247K – 72
2019
Q3 		$247K Hold
2,740
– – 0.01% 67
2019
Q2 		$231K Buy
+2,740
New +$225K 0.01% 77
2017
Q4 		– Sell
-6,640
Closed -$407K – 77
2017
Q3 		$407K Hold
6,640
– – 0.02% 59
2017
Q2 		$305K Sell
6,640
-615,705
-99% -$29.9M 0.02% 57
2017
Q1 		$26.9M Buy
+622,345
New +$26.7M 1.75% 22
2013
Q3 		– Sell
-580,500
Closed -$7.77M – 57
2013
Q2 		$7.77M Buy
+580,500
New +$7.13M 1.37% 29

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Redmile Group's NBIX Position: Q4 2019 in Review

Redmile Group sold out of Neurocrine Biosciences (NBIX) in Q4 2019, closing a stake of 2,740 shares — an estimated $247K sold.

Redmile Group first reported a position in NBIX in Q2 2013 and held it in 6 quarters. The position peaked at $26.9M in Q1 2017. 392 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

  • Redmile Group reported no remaining Neurocrine Biosciences position as of Q4 2019 after selling out during the quarter.
  • Redmile Group sold 2,740 Neurocrine Biosciences shares in Q4 2019, an estimated $247K.
  • Redmile Group first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 6 quarters.
  • Redmile Group's Neurocrine Biosciences position peaked at $26.9M in Q1 2017.
  • 392 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.